Introduction
Colivelin (CLN) has been studied for its potential to prevent and treat neurodegenerative diseases by promoting neuron survival and reducing apoptosis. Colivelin shows promise in research focused on conditions like Alzheimer’s disease, offering insights into its mechanisms and potential therapeutic benefits for brain health. While Colivelin is strictly intended for research chemical use, its ability to shield neurons from harm has made it a focus of scientific investigation.
What is Colivelin (CLN)?
Colivelin (CLN) is a rare peptide that has shown promising potential in preserving neurons in scientific research. It’s a mixture of two substances: the powerful Humanin (HN) derivative AGA-(C8R)HNG17, and the activity-dependent neurotrophic factor (ADNF). Colivelin has shown remarkable efficacy in preventing cell death brought on by Alzheimer’s disease-related genes and amyloid-beta (A) proteins. [R]
The building blocks of Colivelin are the neuroprotective chemicals Adeno-associated nuclear factor (ADNF) and AGA-(C8R)HNG17. Humanin (HN) was first discovered as a peptide with extraordinary properties to protect neurons from toxicity produced by insults associated with AD. Based on these findings, researchers developed a new protein called Colivelin that significantly outperforms both ADNF and AGA-(C8R)HNG17 in terms of neuroprotection.[R]
Colivelin’s outstanding neuroprotective properties are undeniable. It has the highest potency of any HN derivative discovered to date. Cell death induced by genes and Aβ proteins associated with AD can be prevented by extremely low quantities of Colivelin (as low as 100 femtomolar [fM]). Colivelin’s extreme effectiveness means it will be used extensively in the study and possible treatment of neurodegenerative illnesses. [R]
Key Features
RCD.Bio offers Colivelin with the following specifications:
- A purity of 98%, verified by third-party laboratory testing.
- Available in Peptide Form: 100mg
- CAS Number: 867021-83-8
- Molecular weight: 2645.1g/mol
- Chemical Formula: C119H206N32O35
- IUPAC Name: (2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid
How Does It Work?
One of the distinguishing features of Colivelin is its unique ability to activate both STAT3- and CaMKIV-mediated prosurvival pathways. By engaging these molecular pathways, Colivelin empowers neurons to resist AD-relevant insults and maintain their functionality. This multi-faceted approach to neuroprotection sets Colivelin apart from other compounds and underscores its potential as a pivotal asset in future research endeavors. [R]
Potential Benefits of Colivelin
Numerous research investigations and trials on animals suggest that Colivelin may have a number of benefits.
Colivelin and Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a debilitating motor neuron disease that affects a significant number of individuals worldwide. With no sufficiently effective therapy available, the search for novel treatment options continues. In a recent study, researchers explored the potential of Colivelin, a synthetic hybrid peptide composed of activity-dependent neurotrophic factor (ADNF) and AGA-(C8R)HNG17, in improving motor performance and prolonging survival in ALS mice.
The results of the study demonstrated that the i.c.v. injection of Colivelin dose-dependently improved motor performance and prolonged the survival of ALS mice. Furthermore, histological analysis conducted at the age of 120 days revealed increased motoneuronal survival in the spinal cords of Colivelin-treated mice compared to those treated with saline or ADNF alone. These findings highlight the potential of Colivelin as a neurotrophic peptide for ALS treatment. [R]
While further research is necessary to fully understand its mechanism of action and assess its safety and efficacy in human trials, these findings offer hope for individuals living with ALS.
Colivelin and Fetal Alcohol Exposure
Fetal alcohol exposure can have detrimental effects on the developing brain, leading to cell death through apoptosis. However, recent research has uncovered a potential protective peptide called Colivelin (CLN) that shows promise in preventing alcohol-induced apoptosis. This novel peptide has demonstrated the ability to enhance the viability of primary cortical neurons exposed to alcohol, offering potential neuroprotective effects.
Apoptosis, a form of programmed cell death, plays a significant role in the damage caused by fetal alcohol exposure. In the mouse model, pregnant females were assigned to various groups, including those exposed to an ethanol liquid diet, pair-fed controls, and a normal chow group. The findings revealed that CLN effectively blocked the alcohol-induced decline in brain weight and prevented apoptosis by inhibiting caspase-3 activation. CLN also maintained normal levels of cytochrome c, preventing its release from the mitochondria into the cytosol, a key event in neuronal apoptosis. [R]
Further research is required to determine the complete mechanisms underlying CLN’s actions and to improve its application in neuroprotection against fetal alcohol exposure.
CLN and Alzheimer’s Disease
Alzheimer’s disease (AD) is the leading cause of dementia, yet effective treatments remain elusive. In this regard, Colivelin (CLN), a powerful derivative of humanin, has shown promise in preventing cell death induced by genes associated with aβ deposition neuronal in the brain with AD. Hippocampal injection of CLN has demonstrated that CLN antagonizes neuronal loss and has the potential to protect against Aβ-induced memory and synaptic deficits, as well as alleviate the impairment of spatial working memory in hippocampus-induced rats. Building upon these findings, researchers sought to explore the effects of long-term administration of CLN via the nasal route in AD mice, specifically assessing cognitive behaviors, pathological markers, and the electrophysiological mechanism involved.[R] CLN, as a brain penetrant neuroprotective peptide, holds significant potential in antagonizing neuronal loss and improving cognitive function, particularly in the context of memory impairment associated with AD.
Continued research and exploration of CLN’s mechanisms of action may contribute to the development of potential therapeutic strategies for individuals affected by AD and other neurodegenerative diseases. However, it is important to note that Colivelin is strictly intended for research use only and not for human consumption with neurological deficits.
Colivelin and Sepsis-Associated Endothelial Dysfunction
Endothelial dysfunction plays a critical role in the development of multiple organ failure during sepsis. The glycocalyx, a protective layer covering blood vessels, is particularly vulnerable to injury during infection. Colivelin, a synthetic derivative of the mitochondrial peptide humanin, has demonstrated cytoprotective effects in oxidative conditions. Research emphasizes the importance of glycocalyx damage’s early role in sepsis and provides more evidence that colivelin may have therapeutic promise in the management of endothelial dysfunction related to sepsis. [R]
Colivelin and Ischemic Brain Injury
Colivelin’s neuroprotective effects extend to ischemic brain injury and explore the underlying mechanisms involved. In a study, researchers employed a mouse model of transient focal cerebral ischemia and reperfusion to evaluate the impact of Colivelin administration. The study resulted in the upregulation of anti-apoptotic genes and activation of JAK/STAT3 signaling following ischemic stroke. These effects of Colivelin were associated with its capacity to rescue ischemic neuronal death, inhibit axonal damage, and promote axonal growth. The study highlights the potential of Colivelin as a therapeutic agent, either alone or as an adjunct therapy, for ischemic stroke. Further research is needed to explore the full therapeutic potential as colivelin in rescuing ischemic neurons and their possible neurological outcomes.[R]
Precautions To Consider
When researching the use of Colivelin, it is essential to take certain precautions. Here are some precautions to keep in mind:
Observe best practices for studying research chemicals: Studying research chemicals requires a responsible and informed approach to ensure safety and meaningful scientific exploration. Research chemicals, also known as designer drugs or experimental compounds, are substances synthesized for scientific investigation or exploration of their properties.
Follow recommended dosage: Adhere to the recommended dosage instructions outlined on the product label. Avoid exceeding the suggested dose to minimize the risk of potential adverse effects among test subjects.
Potential Side Effects
Currently, there is a lack of information regarding any known side effects associated with CLN. However, it is crucial to emphasize that comprehensive research is necessary to fully comprehend the potential long-term effects of this chemical. Careful evaluation through rigorous scientific investigations will help provide a clearer understanding of the safety profile and any potential risks associated with CLN usage.
Where Can I Buy Colivelin Online?
RCD.bio offers Colivelin for laboratory and research use only.
When buying Colivelin, it is important to choose a reputable seller who provides quality Colivelin. At RCD.bio, each product is accompanied by a third-party-issued Certificate of Analysis showing the identification, purity, and concentration of our product.
Conclusion
Colivelin is a unique peptide that has been demonstrated to protect neurons and stop cell death caused by neurodegenerative disorders. The two components are activity-dependent neurotrophic factor and AGA-(C8R)HNG17, a Humanin derivative (ADNF). Colivelin has been found to have exceptional neuroprotective qualities, especially against amyloid-beta proteins and genes associated with Alzheimer’s disease. It helps synaptic plasticity deficits by acting as a potent activator of certain chemical pathways. Colivelin has recently been investigated for its therapeutic potential in a variety of diseases and disorders, including amyotrophic lateral sclerosis (ALS), fetal alcohol exposure, and spatial working memory induced by Alzheimer’s disease. These studies have shown that Colivelin can improve motor performance, prevent alcohol-induced apoptosis, and protect against memory and synaptic impairments. Its mechanisms of action, safety, and efficacy, however, require additional study. The long-term effects and risks of using Colivelin to treat plasticity deficits in neurodegenerative disease do not eliminate the need for extensive research.
Disclaimer
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before making a purchase from RCD.bio. By completing your order and submitting payment, you agree to abide by our Terms and Conditions. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If for any reason you are not completely satisfied with the product you receive, please contact us at support@rcdbio.co. Our team is dedicated to ensuring customer satisfaction and will be happy to assist you.
PLEASE NOTE: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.
